In the previous meeting, the National Health Insurance Bureau said that impurities in Apis would not be considered in this round of centralized procurement. This basically points to metformin, which has been listed in the second round of centralized mining. It is reported that the product was lost in the final list due to impurity problems at that time, while this time it was shortlisted in the third batch, including three specifications of sustained-release and controlled-release dosage forms and metformin sustained-release tablets. In addition, valsartan, which is also involved in impurity waves, was also shortlisted in this list.
In addition, apixaban, omeprazole, two male ed drugs, sildenafil and dapoxetine, which were originally developed by Pfizer / Bristol Myers Squibb, were also included in the catalogue. The volume purchase will also collect three mainstream ed drugs, sildenafil, Tadanafil and dapoxetine, which can be called a mans gospel.
According to the document, public medical and health institutions at all levels and military medical institutions are required to fill in the data, and non-public medical institutions designated by medical insurance and retail pharmacies are encouraged to fill in the data voluntarily and truthfully. It is required to complete the final data filling before the end of work on July 1, and the municipal and state medical insurance departments must complete the data auditing within their jurisdiction before the end of work on July 3.
At the same time, the document emphasizes that the reported data directly affects the remaining funds of medical institutions and requires relevant medical institutions to report the amount truthfully.